Basilea Pharmaceutica AG, an antibiotic development company spun out of F. Hoffmann-La Roche Ltd. in October 2000, is moving its novel cephalosporin BAL5788 into a Phase III trial, following a successful Phase II study of the drug in patients with complicated skin and skin-structure infections.
The Basel, Switzerland-based firm also is launching an initial public offering in Switzerland, combined with a private placing of shares with overseas investors. It has not revealed details of that transaction.
BAL5788, which received fast-track designation from the FDA 12 months ago, exhibits broad-spectrum activity against a range of Gram-positive and Gram-negative bacterial …
Комментариев нет:
Отправить комментарий